AstraZeneca plc., Bayer AG, Merck & Co., Inc., Sanofi, Pfizer, Inc., and Eli Lilly & Company are a few of the major firms active in the global Cardiovascular Drugs Market and are profiled in the report. These firms are implementing organic and non-organic growth tactics to broaden their range of available goods, improve their regional coverage, build up their clientele, and capture market share. For instance, in December 2015, AstraZeneca purchased ZS Pharma, expanding its portfolio of Cardiovascular Drugs by adding a biological therapy for chronic heart failure. In another case, Sanofi introduced Praluent, a novel cardiovascular medication, in 2016 to treat hyperlipidemia.
The U.S. Food and Drug Administration (FDA) gave the Sun Pharmaceutical Industries subsidiary in the United States permission to sell generic versions of its Coreg CR in October 2017. High blood pressure and heart failure are two problems that Coreg CR is used to treat. In order to create new treatments for heart failure and cardiovascular disorders, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals partnered in August 2017.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/01/cardiovascular-drugs-market-emerging.html
